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Temsirolimus is an inhibitor of mammalian target of rapamycin, with proven efﬁcacy against advanced
renal cell carcinoma (RCC), particularly poor risk and/or non-clear cell RCC, in a randomized ﬁrst-line
phase III trial. In this trial, adverse events (AEs) ≥grade 3 occurred in 47.6% of patients treated with
temsirolimus alone (n＝208), and the common AEs included asthenia, anemia and hyperglycemia. During
the observation period of this trial, drug-related pneumonitis was detected ; 4 patients developed
temsirolimus-related pneumonitis, including 2 with ≥grade 3. To date, there have not been any reports
analyzing data from a large number of Japanese RCC patients treated with temsirolimus. However, judging
from our experience, the severity as well as the frequency of AEs associated with temsirolimus in Japanese
patients seem to be similar to those in the Western population. In this study, we summarize our clinical
experience with the use of temsirolimus focusing on its AEs and try to clarify the characteristics of
temsirolimus-related AEs in Japanese patients, and then present our data relevant to this point from our
clinical studies in order to discuss the signiﬁcance of the management of AEs encountered during treatment
with temsirolimus.
(Hinyokika Kiyo 58 : 651-654, 2012)




















Temsirolimus は mammalian target of rapamycin
(mTOR) 活性を阻害することにより，抗腫瘍効果を







は，Hudes らが実施した global ARCC trial の報告で明
らかになった1)．それによると未治療で poor risk に分
類される転移性腎細胞癌626例を temsirolimus 単独群，









中でも poor risk 症例や非淡明細胞癌症例に対する
ﬁrst-line の標準治療薬としての地位を確立した．
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Table 1. Major adverse events occurring in 208 pa-
tients who were treated with temsirolimus
in Global ARCC trial














Global ARCC trial における temsirolimus 単独群で
は，93.8％に有害事象の出現を認め，grade 3 以上の
有害事象は47.6％に出現した．この結果，93.2％に治
療計画通りの投与 (25 mg/week) が可能であり，
temsirolimus の平均投与量は 23. 1 mg/week であっ
















害事象に対する減量および休薬指針の概要を Fig. 1 に
示す．
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し，temsirolimus は 6例が 20 mg/m2/week にて，76例













経験を要約する．当科では Global ARCC trial の結果
に基づき，poor risk 症例および非淡明細胞癌症例に対
して ﬁrst-line の治療として temsirolimus を投与する
他，その理由は後に述べるが performance status (PS)
不良例に対しては前治療の有無を問わず temsirolimus
を積極的に投与している．実際上記 30例中 10例















は，best response としての PR ，SD および PD が，そ








Table 2. Major adverse events occurring in 30 pa-
tients who were treated with temsirolimus
at Kobe University Hospital
























を調査している．Sorafenib あるいは sunitinib 投与例
における結果はすでに報告したが11,12)，有害事象が
TKI 投与後の QOL に与える影響は限定的なもので
あった．Temsirolimus 導入例においても同様の傾向を
認め，temsirolimus の導入前後で SF-36 の全 8項目に















る KL-6，SPA (surfactant protein A) および SPD13) を





















1) Hudes G, Carducci M, Tomczak P, et al. : Temsiro-
limus, interferon alfa, or both for advanced renal-cell
carcinoma. N Engl J Med 356 : 2271-2281, 2007
2) Voss MH, Molina AM and Motzer RJ : mTOR
inhibitors in advanced renal cell carcinoma. Hematol
Oncol Clin North Am 25 : 835-852, 2011
3) Dazert E and Hall MN : mTOR signaling in disease.
Curr Opin Cell Biol 23 : 744-755, 2011
4) Hutson TE, Figlin RA, Kuhn JG, et al. : Targeted
therapies for metastatic renal cell carcinoma : an
overview of toxicity and dosing strategies. Oncologist
13 : 1084-1096, 2008
5) Eisen T, Sternberg CN, Robert C, et al. : Targeted
therapies for renal cell carcinoma : review of adverse
event management strategies. J Natl Cancer Inst
104 : 93-113, 2012
6) Maroto JP, Hudes G, Dutcher JP, et al. : Drug-related
pneumonitis in patients with advanced renal cell
carcinoma treated with temsirolimus. J Clin Oncol
29 : 1750-1756, 2011
7) Bellmunt J, Szczylik C, Feingold J, et al. : Temsiro-
limus safety proﬁle and management of toxic effects in
patients with advanced renal cell carcinoma and poor
prognostic features. Ann Oncol 19 : 1387-1392,
2008
8) Akaza H, Tsukamoto T, Murai M, et al. : Phase II
study to investigate the efﬁcacy, safety, and pharmaco-
kinetics of sorafenib in Japanese patients with ad-
vanced renal cell carcinoma. Jpn J Clin Oncol 37 :
755-762, 2007
9) Uemura H, Shinohara N, Yuasa T, et al. : A phase II
study of sunitinib in Japanese patients with metastatic
renal cell carcinoma : insights into the treatment, efﬁ-
cacy and safety. Jpn J Clin Oncol 40 : 194-202, 2010
10) Fukuhara S, Bito S, Green J, et al. : Translation,
adaptation, and validation of the SF-36 Health Survey
for use in Japan. J Clin Epidemiol 51 : 1037-1044,
1998
11) Miyake H, Kurahashi T, Yamanaka K, et al. : Impact
of sorafenib on health-related quality of life in Japanese
patients with metastatic renal cell carcinoma : a pro-
spective evaluation. BJU Int 106 : 1643-1647, 2010
12) Miyake H, Harada KI, Kusuda Y, et al. : Health-
related quality of life in Japanese patients with
metastatic renal cell carcinoma treated with sunitinib.
Int J Clin Oncol, in press
13) Ohnishi H, Yokoyama A, Kondo K, et al. : Compar-
ative study of KL-6, surfactant protein-A, surfactant
protein-D, and monocyte chemoattractant protein-1 as
serum markers for interstitial lung diseases. Am J
Respir Crit Care Med 165 : 378-381, 2002
(
Received on June 26, 2012
)Accepted on July 17, 2012
泌尿紀要 58巻 11号 2012年654
